Proposed New Pathophysiology of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
The most common type of prostatitis is category III, also known as chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The current National Institutes of Health definition of CP/CPPS includes genitourinary pain with or without voiding symptoms in the absence of uropathogenic bacteria, as detected by standard microbiological methods, or other identifiable causes such as malignancy. Many different etiologies and mechanisms of pathogenesis of CP/CPPS have been proposed with a suggested role for immunological, neurological, endocrine, and psychological factors. We examined the data supporting the role of each of these areas and also examined the possible interrelationship of these factors in producing the symptoms of CP/CPPS. Prostatitis types IIIa and IIIb are classified according to the presence of pain without concurrent presence of bacteria; however, it is becoming more evident that, although levels of bacteria are not directly associated with levels of pain, the presence of bacteria might act as the initiating factor that drives primary activation of mast-cell-mediated inflammation in the prostate. The gate control theory provides a neurologic basis for the influence of both somatic and psychological factors on pain. Acceptance of chronic pain as a diagnosis may be difficult for the clinician and patient, however it is an important concept in the care of CP/CPPS, which enables the use of pain-directed therapies. Management of CP/CPPS will remain challenging; however, this review provides a better understanding of the condition and improved management strategies based on the newest evidence and concepts available.
Abstract
The most common type of prostatitis is category III, also known as chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The current National Institutes of Health definition of CP/CPPS includes genitourinary pain with or without voiding symptoms in the absence of uropathogenic bacteria, as detected by standard microbiological methods, or other identifiable causes such as malignancy. Many different etiologies and mechanisms of pathogenesis of CP/CPPS have been proposed with a suggested role for immunological, neurological, endocrine, and psychological factors. We examined the data supporting the role of each of these areas and also examined the possible interrelationship of these factors in producing the symptoms of CP/CPPS. Prostatitis types IIIa and IIIb are classified according to the presence of pain without concurrent presence of bacteria; however, it is becoming more evident that, although levels of bacteria are not directly associated with levels of pain, the presence of bacteria might act as the initiating factor that drives primary activation of mast-cell-mediated inflammation in the prostate. The gate control theory provides a neurologic basis for the influence of both somatic and psychological factors on pain. Acceptance of chronic pain as a diagnosis may be difficult for the clinician and patient, however it is an important concept in the care of CP/CPPS, which enables the use of pain-directed therapies. Management of CP/CPPS will remain challenging; however, this review provides a better understanding of the condition and improved management strategies based on the newest evidence and concepts available.
참고문헌 (63)
- Krieger JN, "NIH consensus definition and classification of prostatitis", JAMA, 282, pp.236~237 (1999)
- Collins MM, "Prevalence and correlates of prostatitis in the health professionals follow-up study cohort", J Urol, 167, pp.1363~1366 (2002)
- Mehik A, "Epidemiology of prostatitis in Finnish men: a population-based cross-sectional study", BJU Int, 86, pp.443~448 (2000)
- Schaeffer AJ, "Demographic and clinical characteristics of men with chronic prostatitis: the national institutes of health chronic prostatitis cohort study", J Urol, 168, pp.593~598 (2002)
- Nickel JC, "Leukocytes and bacteria in men with chronic prostatitis", chronic pelvic pain syndrome compared to asymptomatic controls, 2003, pp.170, 818~822
- Leskinen MJ, "Herpes simplex virus, cytomegalovirus, and papillomavirus DNA are not found in patients with chronic pelvic pain syndrome undergoing radical prostatectomy for localized prostate cancer", Urology, 61, pp.397~401 (2003)
- Leskinen MJ, "Negative bacterial polymerase chain reaction (PCR) findings in prostate tissue from patients with symptoms of chronic pelvic pain syndrome (CPPS) and localized prostate cancer", Prostate, 55, pp.105~110 (2003)
- Shoskes DA, "Detection of bacterial signal by 16SrRNA polymerase chain reaction in expressed prostatic secretions predicts response to antibiotic therapy in men with chronic pelvic pain syndrome", Tech Urol, 6, pp.240~242 (2000)
- Kanbay M, "Helicobacter pylori seroprevalence in patients with chronic bronchitis", Respir Med, 99, pp.1213~1216 (2005)
- Mendall MA, "Relation of Helicobacter pylori infection and coronary heart disease", Br Heart J, 71, pp.437~439 (1994)
- Rebora A, "Helicobacter pylori in patients with rosacea", Am J Gastroenterol, 89, pp.1603~1604 (1994)
- Karatas OF, "Helicobacter pylori seroprevalence in patients with chronic prostatitis: a pilot study", Scand J Urol Nephrol, 44, pp.91~94 (2010)
- Geramoutsos I, "Clinical correlation of prostatic lithiasis with chronic pelvic pain syndromes in young adults", Eur Urol, 45, pp.333~337 (2004)
- Shoskes DA, "Anti-nanobacterial therapy for men with chronic prostatitis", chronic pelvic pain syndrome and prostatic stones: preliminary experience, 2005, pp.173, 474~477
- Wood HM, "The role of nanobacteria in urologic disease", World J Urol, 24, pp.51~54 (2006)
- Zhou Z, "Detection of nanobacteria infection in type III prostatitis", Urology, 71, pp.1091~1095 (2008)
- Weidner W, "Chronic prostatitis: a thorough search for etiologically involved microorganisms in 1,461 patients", Infection, 19(Suppl 3), pp.S119~S125 (1991)
- Pontari MA, "A case-control study of risk factors in men with chronic pelvic pain syndrome", BJU Int, 96, pp.559~565 (2005)
- Rudick CN, "Uropathogenic Escherichia coli induces chronic pelvic pain", Infect Immun, 79, pp.628~635 (2011)
- True LD, "Prostate histopathology and the chronic prostatitis", chronic pelvic pain syndrome: a prospective biopsy study, 1999, pp.162, 2014~2018
- Nickel JC, "The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial", Eur Urol, 54, pp.1379~1384 (2008)
- Schaeffer AJ, "Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: the National Institutes of Health Chronic Prostatitis Cohort Study", J Urol, 168, pp.1048~1053 (2002)
- Hochreiter WW, "Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions", Urology, 56, pp.1025~1029 (2000)
- Nadler RB, "IL-1beta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis", J Urol, 164, pp.214~218 (2000)
- Desireddi NV, "Monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha as possible biomarkers for the chronic pelvic pain syndrome", J Urol, 179, pp.1857~1861 (2008)
- Thumbikat P, "Prostate secretions from men with chronic pelvic pain syndrome inhibit proinflammatory mediators", J Urol, 184, pp.1536~1542 (2010)
- Miller LJ, "Nerve growth factor and chronic prostatitis", chronic pelvic pain syndrome, 2002, pp.59, 603~608
- Watanabe T, "Nerve growth factor level in the prostatic fluid of patients with chronic prostatitis", chronic pelvic pain syndrome is correlated with symptom severity and response to treatment, 2011, pp.108, 248~251
- Woolf CJ, "The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of postinjury pain hypersensitivity states", Pain, 44, pp.293~299 (1991)
- Davis SN, "Tenderness as measured by pressure pain thresholds extends beyond the pelvis in chronic pelvic pain syndrome in men", J Sex Med, 8, pp.232~239 (2011)
- Bennett MI, "Gabapentin in the treatment of neuropathic pain", Palliat Med, 18, pp.5~11 (2004)
- Rose MA, "Gabapentin: pharmacology and its use in pain management", Anaesthesia, 57, pp.451~462 (2002)
- Guay DR, "Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin", Am J Geriatr Pharmacother, 3, pp.274~287 (2005)
- Gajraj NM, "Pregabalin: its pharmacology and use in pain management", Anesth Analg, 105, pp.1805~1815 (2007)
- Chiechio S, "Pregabalin in the treatment of chronic pain: anoverview", Clin Drug Investig, 29, pp.203~213 (2009)
- Tripp DA, "Predictors of quality of life and pain in chronic prostatitis", chronic pelvic pain syndrome: findings from the National Institutes of Health Chronic Prostatitis Cohort Study, 2004, pp.94, 1279~1282
- Tripp DA, "A 2-year follow-up of quality of life, pain, and psychosocial factors in patients with chronic prostatitis", chronic pelvic pain syndrome and their spouses, 2013, pp.31, 733~739
- Zhang GX, "A preliminary evaluation of the psychometric profiles in Chinese men with chronic prostatitis", chronic pelvic pain syndrome, 2011, pp.124, 514~518
- 안선국, "Depression, Anxiety, Stress Perception, and Coping Strategies in Korean Military Patients with Chronic Prostatitis", Chronic Pelvic Pain Syndrome, 2012, pp.53(9), 643~648[DOI]
- Anderson RU, "Stress induced hypothalamus-pituitary-adrenal axis responses and disturbances in psychological profiles in men with chronic prostatitis", chronic pelvic pain syndrome, 2009, pp.182, 2319~2324
- Anderson RU, "Psychometric profiles and hypothalamic-pituitary-adrenal axis function in men with chronic prostatitis", chronic pelvic pain syndrome, 2008, pp.179, 956~960
- Beck AT, "An inventory for measuring clinical anxiety: psychometric properties", J Consult Clin Psychol, 56, pp.893~897 (1988)
- Clemens JQ, "Mental health diagnoses in patients with interstitial cystitis", painful bladder syndrome and chronic prostatitis, control study, pp.J Urol, 2008[DOI]
- Chung SD, "Association between chronic prostatitis", chronic pelvic pain syndrome and anxiety disorder: a population-based study, 2013, pp.8, e64630~
- Tripp DA, "Catastrophizing and pain-contingent rest predict patient adjustment in men with chronic prostatitis", chronic pelvic pain syndrome, 2006, pp.7, 697~708
- Nickel JC, "Psychosocial variables affect the quality of life of men diagnosed with chronic prostatitis", chronic pelvic pain syndrome, 2008, pp.101, 59~64
- Hu JC, "The association of abuse and symptoms suggestive of chronic prostatitis", chronic pelvic pain syndrome: results from the Boston Area Community Health survey, 2007, pp.22, 1532~1537
- Spanos C, "Stress-induced bladder mast cell activation: implications for interstitial cystitis", J Urol, 157, pp.669~672 (1997)
- Keast JR, "Differential regulation of trkA and p75 in noradrenergic pelvic autonomic ganglion cells after deafferentation of their cholinergic neighbours", Eur J Neurosci, 13, pp.211~220 (2001)
- Meusburger SM, "Testosterone and nerve growth factor have distinct but interacting effects on structure and neurotransmitter expression of adult pelvic ganglion cells in vitro", Neuroscience, 108, pp.331~340 (2001)
- Di Franco M, "Neuroendocrine immunology of fibromyalgia", Ann N Y Acad Sci, 1193, pp.84~90 (2010)
- McEwen BS, "The role of corticosteroids and stress in chronic pain conditions", Metabolism, 59(Suppl 1), pp.9~15 (2010)
- Dimitrakov J, "Adrenocortical hormone abnormalities in men with chronic prostatitis", chronic pelvic pain syndrome, 2008, pp.71, 261~266
- Kroeger KM, "The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription", Mol Immunol, 34, pp.391~399 (1997)
- Turner DM, "An investigation of polymorphism in the interleukin-10 gene promoter", Eur J Immunogenet, 24, pp.1~8 (1997)
- Shoskes DA, "Cytokine polymorphisms in men with chronic prostatitis", chronic pelvic pain syndrome: association with diagnosis and treatment response, 2002, pp.168, 331~335
- Riley DE, "X Chromosomal short tandem repeat polymorphisms near the phosphoglycerate kinase gene in men with chronic prostatitis", Biochim Biophys Acta, 1586, pp.99~107 (2002)
- Arisan ED, "Manganese superoxide dismutase polymorphism in chronic pelvic pain syndrome patients", Prostate Cancer Prostatic Dis, 9, pp.426~431 (2006)
- Dimitrakov J, "Genetics and phenotyping of urological chronic pelvic pain syndrome", J Urol, 181, pp.1550~1557 (2009)
- Klein RJ, "Complement factor H polymorphism in age-related macular degeneration", Science, 308, pp.385~389 (2005)
- Nickel JC, "Campbell-Walsh urology", pp.333~ (2012), Saunders
- Murphy SF, "Immune mediators of chronic pelvic pain syndrome", Nat Rev Urol, 11, pp.259~269 (2014)
- Rapkin AJ, "Neuroanatomy, neurophysiology, and neuropharmacology of pelvic pain", Clin Obstet Gynecol, 33, pp.119~129 (1990)